TD Cowen Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
Tweet Send to a Friend
TD Cowen analyst Joseph Thome, Ph.D reiterated a Buy rating and $200.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
